Filtered By:
Management: Government
This page shows you your search results in order of relevance. This is page number 16.
Order by Relevance | Date
Total 334 results found since Jan 2013.
First Coronavirus Vaccine Tested in Humans Shows Early Promise
The vaccine, developed by government scientists and Moderna, a biotech company, appeared safe and provoked an immune response in 45 people in a study.
Source: NYT Health - July 15, 2020 Category: Consumer Health News Authors: Denise Grady Tags: your-feed-science Vaccination and Immunization Coronavirus (2019-nCoV) Immune System Moderna Inc National Institute of Allergy and Infectious Diseases New England Journal of Medicine Source Type: news
Trump Signs Four Executive Orders Aimed at Cutting Drug Prices Trump Signs Four Executive Orders Aimed at Cutting Drug Prices
President Trump on Friday outlined actions he would like the federal government to take to lower drug prices. These included clearing the way for importing cheaper drugs from abroad.Medscape Medical News
Source: Medscape Allergy Headlines - July 27, 2020 Category: Allergy & Immunology Tags: Family Medicine/Primary Care News Source Type: news
Moderna Coronavirus Vaccine Test in Monkeys Shows Promise
This coronavirus vaccine developed by government researchers and Moderna enabled the animals to quickly clear the infection from their lungs.
Source: NYT Health - July 29, 2020 Category: Consumer Health News Authors: Denise Grady Tags: Vaccination and Immunization Moderna Inc Clinical Trials Tests (Medical) Research Monkeys and Apes National Institute of Allergy and Infectious Diseases New England Journal of Medicine Vaccine (Journal) your-feed-healthcare Coronavirus Source Type: news
U.S. Government to Launch ' Overwhelming ' COVID-19 Vaccine Campaign by November U.S. Government to Launch ' Overwhelming ' COVID-19 Vaccine Campaign by November
The US government anticipates launching a promotions campaign by November to encourage Americans to get vaccinated against COVID, contingent on evidence that a vaccine will be available by year ' s end.Reuters Health Information
Source: Medscape Allergy Headlines - August 3, 2020 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news
US to Pay $2.1 Bln to Sanofi, GSK, in COVID-19 Vaccine Deal US to Pay $2.1 Bln to Sanofi, GSK, in COVID-19 Vaccine Deal
The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drugmakers ' testing and manufacturing.Reuters Health Information
Source: Medscape Allergy Headlines - August 3, 2020 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news
China-Backed Hackers ' Targeted COVID-19 Vaccine Firm Moderna ' China-Backed Hackers ' Targeted COVID-19 Vaccine Firm Moderna '
Chinese government-linked hackers targeted biotech firm Moderna, a US-based coronavirus vaccine research developer, in a bid to steal data, according to a US security official tracking Chinese hacking.Reuters Health Information
Source: Medscape Allergy Headlines - August 3, 2020 Category: Allergy & Immunology Tags: Infectious Diseases News Video Source Type: news
Why the U.S. Is Losing the War On COVID-19
It is a frightening time to live in the United States. COVID-19, a novel disease as ruthless as it is seemingly random, is picking us off by the thousands; even many of those who “recover” may never truly be the same again. The pandemic has exposed the gulf between what this country promises for its citizens and what it actually delivers. And as the U.S. barrels toward Election Day, the outbreak is sure to complicate the voting process, with potentially disastrous results.
For a short time in the spring, it appeared the U.S. was getting a grip on its outbreak. Hard-hit states like New York successfully flattene...
Source: TIME: Health - August 13, 2020 Category: Consumer Health News Authors: Alex Fitzpatrick Tags: Uncategorized COVID-19 UnitedWeRise20Disaster Source Type: news
US to Make Coronavirus Strain for Possible Human Challenge Trials US to Make Coronavirus Strain for Possible Human Challenge Trials
US government scientists have begun efforts to manufacture a strain of the novel coronavirus that could be used in human challenge trials of vaccines, Reuters has learned.Reuters Health Information
Source: Medscape Allergy Headlines - August 17, 2020 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news
Pharmacists Can Vaccinate Kids; Lockdowns Slash Vaccination Levels Pharmacists Can Vaccinate Kids; Lockdowns Slash Vaccination Levels
The US government said pharmacists would be allowed to administer routine vaccines to children, calling a drop in immunization rates during COVID-19 a"public health threat."Reuters Health Information
Source: Medscape Allergy Headlines - August 20, 2020 Category: Allergy & Immunology Tags: Pediatrics News Source Type: news
FDA Issues Emergency Authorization For Convalescent Plasma To Treat Covid-19
(CNN) — The US Food and Drug Administration on Sunday issued an emergency use authorization for convalescent plasma to treat Covid-19, saying the “known and potential benefits of the product outweigh the known and potential risks of the product.”
The FDA said more than 70,000 patients had been treated with convalescent plasma, which is made using the blood of people who have recovered from coronavirus infections.
“Today I am pleased to make a truly historic announcement in our battle against the China virus that will save countless lives,” President Trump said at a White House briefing, referr...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 24, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Health Healthcare Status Syndicated CBSN Boston CNN Coronavirus Source Type: news
Cutaneous Radiation Injuries: Models, Assessment and Treatments.
This report provides an overview of information that was presented and the subsequent guided discussions.
PMID: 32857831 [PubMed - as supplied by publisher]
Source: Radiation Research - August 27, 2020 Category: Physics Authors: DiCarlo AL, Bandremer AC, Hollingsworth BA, Kasim S, Laniyonu A, Todd NF, Wang SJ, Wertheimer ER, Rios CI Tags: Radiat Res Source Type: research
The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins.
Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen ’s COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., September 23, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development. These results have been submitted to medRxiv and are due to be published online imminentl...
Source: Johnson and Johnson - September 23, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
The FDA Is Slowing Down COVID-19 Vaccine Approval. That Could Be Good for Public Health
New U.S. Food and Drug Administration (FDA) guidance means a COVID-19 vaccine likely will not be approved by Election Day—which could actually be a good thing for public health.
On Oct. 6, the agency posted an industry guidance document on its website asking pharmaceutical companies applying for emergency-use authorization of a COVID-19 vaccine to monitor study subjects for at least two months after vaccination, so they can look for side effects that may arise over time and get a better sense of the shot’s efficacy. That means it’s unlikely any manufacturer will receive authorization before Election Day o...
Source: TIME: Health - October 7, 2020 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 Source Type: news
